Management team

Education/experience: Martin Jönsson holds an M.Sc. in business administration from the University of Lund, and has also studied at the University of Freiburg, Germany and the University of Ottawa, Canada. Martin Jönsson has more than 20 years of experience in the global pharmaceutical industry and has held several executive positions, with experience in business development, marketing, sales, alliance management and medical affairs. Previous employers include Roche and Ferring Pharmaceuticals. Martin has worked internationally, including several years in the USA.

Current assignment: None

Completed assignments (last five years): Senior positions in several different areas at Ferring Pharmaceuticals, including business area manager for several therapeutic fields.

Holdings: 409,466 shares and 500,000 share options.

Education/experience: Johan Sandin has a Ph.D. from Karolinska Institutet with a focus on neuropharmacology and with significant international academic and industrial experience (>20 years). He has worked at AstraZeneca since 2003, where he has held scientific, project and executive positions in charge of in vitro biology, in vivo pharmacology and biochemical biomarkers within the CNS field.

Current assignments: Member of the board and CEO at Sandin Pharma Consulting AB. Member of the boards of AC Intressenter AB. CEO of AlzeCure Discovery AB.

Completed assignments (past five years): Member of the board and deputy Managing Director at ArgusEye AB.

Holdings: 875,834 shares.

Education/experience: Birgitta Lundvik has an MSc in business from Uppsala University and an eMBA in finance from Stockholm Business school, Sweden. Birgitta Lundvik has more than 25 years of experience from software development, life science and real estate companies. She has been involved in several M&A projects and has broad experience of venture capital companies.

Current assignment: Chairman of the Board of HERAccount AB. Member of the board and CEO of Enable – Finance & Business Development in Sweden AB. Alternate member of the board of Helander & Lundvik Ekonomikonsulter AB, Balanced Competence Uppsala Redovisningsbyrå AB, and Brf Arken.

Completed assignments (last five years): Secretary and Treasurer of Favro North America Inc. Deputy chairman of Swedsoft. Chair of the board of LobSor Pharmaceuticals AB. Member of the board and CEO of Hansoft Technologies AB. CEO of Favro AB and Favro Holding AB.

Holdings: 122,500 shares.

Education/experience: Pontus Forsell holds a Ph.D. in Medical Biochemistry & Biophysics from Karolinska Institutet, Sweden. Pontus Forsell has more than 20 years of experience from several biotech and pharmaceutical companies, such as Biolipox, Orexo, Merck and AstraZeneca in project and management positions. He is an expert in early phase drug development within the disease areas neurology, analgesia and inflammation, as well as respiratory diseases.

Current assignments: Member of the Board and CEO of Research, Education & Training AB (RETAB).

Completed assignments (past five years): None.

Holdings: 907,477 shares.

Education/experience: Märta Segerdahl has an MD, PhD and Associate prof from the Karolinska Institute. Märta has a board certification in Anesthesia and Intensive Care and in Pain Medicine, along with a Diploma in Pharmaceutical Development. Märta has a significant international academic and industrial experience within the area of CNS and Pain. After 25 years in clinical medicine, she joined AstraZeneca in 2006, and since then has experience from Grünenthal, Lundbeck and Asarina Pharma where she has held global leadership and executive positions within translational medicine, external collaborations and clinical development across the CNS area.

Current assignments: Member of the board and CEO at MS Medical Consulting AB. Member of the board and deputy CEO at Christian Storck Management AB.

Completed assignments (past five years): Senior positions at Lundbeck A/S, Asarina Pharma ApS.

Holdings: 74,166 shares.